Highlights Icure Pharmaceutical Incorporation

Equities

A175250

KR7175250000

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
1,818 ^KRW	-1.20%		-1.62%	-13.01%

03-20	Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Tranche Update on Icure Pharmaceutical Incorporation's Equity Buyback Plan announced on February 25, 2022.	22-03-11	CI
Icure Pharmaceutical Incorporation's Equity Buyback announced on February 25, 2022, has closed with 40,323 shares, representing 0.23% for KRW 547.51 million.	22-03-06	CI
Icure Pharmaceutical Incorporation announces an Equity Buyback for 40,323 shares.	22-02-25	CI
Icure Pharmaceutical Incorporation authorizes a Buyback Plan.	22-02-24	CI
Icure Acquires Drug Product Approval for Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea	21-11-16	CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Prostemics Co., Ltd. agreed to acquire OTKCNT Co., Ltd. from Icure Pharmaceutical Incorporation and Gang, Seok-Ho for KRW 17 billion.	20-08-05	CI
Icure Pharm. Inc. cancelled the acquisition of 90% stake in OTKCNT Co., Ltd. from an unknown seller.	20-04-04	CI
Icure Pharm. Inc.'s Equity Buyback announced on August 8, 2019, has expired.	19-09-07	CI
Icure Pharm. Inc. announces an Equity Buyback for 153,061 shares.	19-08-08	CI
Icure Pharm. Inc. authorizes a Buyback Plan.	19-08-07	CI
Icure Pharm. Inc. announced that it expects to receive KRW 40 billion in funding from a group of investors	19-04-15	CI
Icure Pharm. Inc. agreed to acquire 90% stake in OTKCNT Co., Ltd. from an unknown seller for KRW 9 billion.	19-04-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Icure Pharmaceutical Incorporation

Equities

A175250

KR7175250000

Highlights

Filters